Report #2825486

Received Feb 10, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Recovered
Vaccinated: Jan 1, 2025
Onset: Jan 1, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Pyrexia

Symptom narrative

fever; This non-serious case was reported by a consumer and described the occurrence of fever in a patient who received Herpes zoster (Shingrix) for prophylaxis. On 01-JAN-2025, the patient received the 2nd dose of Shingrix. In JAN-2025, less than a week after receiving Shingrix, the patient experienced fever (Verbatim: fever). The outcome of the fever was resolved. It was unknown if the reporter considered the fever to be related to Shingrix. It was unknown if the company considered the fever to be related to Shingrix. Additional Information: GSK Receipt Date: 03-FEB-2025 Patient got second shot of Shingrix and experienced fever.